蘑菇视频

Faculty & Staff

Gargi Ghosh, PhD

Gargi Ghosh, PhD, joined the Amgen Bioprocessing Center in the Henry E. Riggs School of Applied Life Sciences at 蘑菇视频 Institute (KGI) as an Associate Professor in August 2022. Prior to this, she was a tenured faculty member in the Mechanical Engineering Department at the University of Michigan-Dearborn. Before her tenure at Michigan, Ghosh worked as a Postdoctoral Fellow with Professor Sean Palecek at the University of Wisconsin, Madison, and Professor Stephen Kron at the University of Chicago. Earlier, Ghosh earned her PhD from the Department of Chemical and Materials Engineering at the University of Kentucky. Ghosh obtained master鈥檚 and bachelor鈥檚 degrees in Chemical Engineering from the Indian Institute of Technology Kanpur and the University of Calcutta, India, respectively. Her research interests center on stem cell therapy and regenerative medicine, with a focus on advancing innovative solutions in these fields.

  1. Somadder R, Faraj L, Datta S, Kanapathipillai M, Ghosh, G. Effect of extracellular matrices on production and potency of mesenchymal stem cell-derived exosomes. Biotechnology Journal. 2024; 19: 2300474.
  2. Orabi M, Ghosh G. Investigating the interplay between matrix compliance and passaging history on chondrogenic differentiation of mesenchymal stem cells encapsulated within alginate-gelatin hybrid hydrogels. Ann Biomed Eng. 2023; 51: 2722-2734.
  3. Nasser M, Ghosh G. Engineering tumor constructs to study matrix-dependent angiogenic signaling of breast cancer cells. Biotech Prog. 2022; 38: e3250.
  4. Sears V, Danaoui Y, Ghosh, G; Impact of mesenchymal stem cell-secretome-loaded hydrogel on proliferative and migratory activities of hyperglycemic fibroblasts. Materials Today Communications. 2021; 27: 102285.
  5. Sears V, Ghosh G; Harnessing mesenchymal stem cell secretome: effect of extracellular matrices on pro-angiogenic signaling. Biotechnology and Bioengineering. 2020; 117:1159-1171.
  6. Nasser M, Wu Y, Danaoui Y, Ghosh, G. Engineering microenvironments towards harnessing pro-angiogenic potential of mesenchymal stem cells. Materials Science and Engineering C, 2019, 102, 75-84.
  7. Wu Y, Fu R, Mohanty S, Nasser M, Guo B, Ghosh G. Investigation of integrated effects of hydroxyapatite and VEGF on capillary morphogenesis of endothelial cells. ACS Applied Bio Materials, 2019, 2, 2339-2346.
  8. El-Mohri H, Wu Y, Mohanty S, Ghosh G. Impact of matrix stiffness on fibroblast function. Materials Science and Engineering C, 2017, 74, 146-151.
  9. Mohanty S, Wu Y, Chakraborty N, Mohanty P, Ghosh G. Impact of alginate concentration on the viability, cryostorage, and angiogenic activity of encapsulated fibroblasts. Materials Science and Engineering C, 2016, 65, 269-277.
  10. Ye M, Mohanty P, Ghosh G. Morphology and properties of poly vinyl alcohol (PVA) scaffolds: impact of process variables. Materials Science and Engineering C, 2014, 42, 289-294.

Our research group at KGI is interested in understanding how alterations in cellular signaling pathways regulate diverse cell functions. By integrating biotechnology, biomaterials science, stem cell biology, and engineering, we aim to elucidate the intricate interactions between stem cells and their extracellular matrices. Our ultimate goal is to enable the clinical translation of stem cells as well as stem-cell derived therapeutic products. Specifically, our focus lies in two key areas: rejuvenating mesenchymal stem cells (MSCs) to enhance their therapeutic potential and optimizing MSC-derived exosomes. These efforts are geared towards developing innovative, scalable solutions for regenerative medicine and advancing the therapeutic applications of stem cell-based technologies.

Mesenchymal stem cells (MSCs), by virtue of their regenerative properties and ability to differentiate into multiple cell lineages, have garnered tremendous interest in cell-based therapies for various diseases and injuries. However, most indications needing MSC therapy require a target production lot size of ~100B cells. Thus, a pre-requisite for the development of the MSC-based therapy is developing technologies/strategies for robust expansion of MSCs. In addition to improving the yield of stem cells, maintaining their functional integrity and therapeutic potential is critical to the success of stem cell-based therapy or therapeutic products. We focus on developing tissue-mimetic culture systems towards reducing senescence and rejuvenating MSCs.MSC-derived exosomes possess regenerative and immunomodulatory properties, more amenable to manipulation, have fewer potential adverse effects, and less immune rejection. However, despite their therapeutic potential, the FDA has yet to approve any exosome-based therapy primarily due to the inherent limitations, including low productivity, lack of scalability, and ineffective targeting. We focus on improving culture conditions to enhance exosome yield and functionality.